Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study
Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study have?
Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study has 0 citations in the OpenAlex counts ScholarIQ stores.
When was Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study published?
Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study has 2024 year in the ScholarIQ index.
What is the open-access status of Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study?
Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study has green oa status in the ScholarIQ index.
What is the DOI of Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study?
The DOI for Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study is on the source record.
What is the OpenAlex record for Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study?
The OpenAlex for Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study is on the source record.